You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 8,900,566


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,900,566 protect, and when does it expire?

Patent 8,900,566 protects DAKLINZA and is included in one NDA.

This patent has sixty-seven patent family members in thirty-one countries.

Summary for Patent: 8,900,566
Title:Hepatitis C virus inhibitors
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Inventor(s): Belema; Makonen (North Haven, CT), Nguyen; Van N. (Middletown, CT)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:14/030,199
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,900,566

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-001 Jul 24, 2015 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY ⤷  Try a Trial
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-001 Jul 24, 2015 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial METHOD OF INHIBITING HEPATITIS C VIRUS ⤷  Try a Trial
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-002 Jul 24, 2015 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY ⤷  Try a Trial
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-002 Jul 24, 2015 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial METHOD OF INHIBITING HEPATITIS C VIRUS ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,900,566

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 063684 ⤷  Try a Trial
Argentina 108411 ⤷  Try a Trial
Australia 2007286222 ⤷  Try a Trial
Brazil PI0716483 ⤷  Try a Trial
Canada 2660520 ⤷  Try a Trial
Chile 2007002327 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.